Bristol-Myers Squibb recently wrapped up a pivotal study in Japan, focusing on the quality of life in patients with ...

UBS Group just sliced their target for CVS Health from $71.00 to $67.00, maintaining a 'neutral' stance. Despite this cut, ...

A lawsuit filed in federal court on behalf of the University of Pennsylvania and its health system alleges that 20 years of skyrocketing prices on drugs that treat diabetes, like insulin, can be ...

Morgan Stanley identifies 15 stocks with potential near-term catalysts for growth, offering insights on upcoming earnings and ...

Morgan Stanley (NYSE:MS) expects a “normal” earnings beat rate for the second quarter, with S&P 500 EPS growth forecast at 5% year-over-year and sales up 4%.

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...

Over half of large US employers plan to cut health benefits in 2026 as rising costs of weight-loss drugs like Wegovy drive up ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

In a report released yesterday, Lance Wilkes from Bernstein maintained a Hold rating on CVS Health, with a price target of $72.00. The company’s shares closed yesterday at $63.80. Wilkes covers the ...

In a report released on July 14, Ben Hendrix from RBC Capital maintained a Buy rating on CVS Health, with a price target of $81.00. The company’s shares closed yesterday at $63.